Clinical Studies

Savara Pharmaceuticals / Development / Clinical Studies

Clinical Studies (Previous and ongoing)

Savara is an orphan lung disease company and our pipeline is comprised of the following inhaled investigational therapies: Molgradex, Apulmiq, and AeroVanc.

MOLGRADEX (inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF) is being evaluated for the following indications:

  • Autoimmune pulmonary alveolar proteinosis (aPAP)
  • Nontuberculous mycobacteria (NTM) lung infection in people living with cystic fibrosis (CF) and NTM in people who are not affected by CF

APULMIQ (inhaled ciprofloxacin) will be evaluated for the treatment of non-cystic fibrosis bronchiectasis (NCFB).

AEROVANC (vancomycin hydrochloride inhalation powder) is being evaluated for the treatment of persistent methicillin-resistant Staphylococcus aureus, or MRSA, lung infection in CF.

Molgradex – aPAP

Molgradex is the first inhaled GM-CSF being developed for the treatment of a rare respiratory disease called autoimmune pulmonary alveolar proteinosis (aPAP). A pivotal Phase 3 clinical study, called IMPALA, was completed in 2019. The press release announcing results from the 24-week, double-blind period of the study can be found here. The press release announcing results from the open-label period can be found here. A second Phase 3 study is being planned.
Read more

Molgradex – NTM

Molgradex was evaluated in a Phase 2a clinical study, called OPTIMA, for the treatment of patients with nontuberculous mycobacterial (NTM) lung infection, a rare and serious lung disorder associated with increased rates of morbidity and mortality. The press release announcing topline results of the study can be found here. The next steps for this program will be determined once results from the ENCORE study (which is evaluating Molgradex for the treatment of NTM in people living with CF) are available.
Read more

Molgradex – NTM in CF

Molgradex is being evaluated in a Phase 2a clinical study, called ENCORE, for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with CF. NTM is a rare and serious lung disorder associated with increased rates of morbidity and mortality.
Read more

AeroVanc – MRSA in CF

AeroVanc is the first inhaled antibiotic being developed to address the growing problem of chronic methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people with CF. A pivotal Phase 3 clinical study, called AVAIL, is ongoing.
Read more

Summary of Savara’s U.S. Expanded Access Policy

Back to Top
Savara Nasdaq Opening Bell Ceremony - July 23, 2018
×

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies allow us to count visits and traffic sources, so we can measure and improve the performance of our site.

We track anonymized user information to improve our website.
  • _ga
  • _gid
  • _gat

Google Analytics works by means of tracking code that is added to the pages of our website. Every user is registered with a unique ID, so that Google Analytics can provide us with insight into how many unique visitors there are to the site, for example, and how many users return. With Google Analytics, we can survey how often any single user has visited the website, what pages they visited, for how long they stayed and how they interacted with the site.
  • __utma
  • __utmt
  • __utmb
  • __utmz
  • __utmv

Decline all Services
Accept all Services